Acute intermittent porphyria (AIP), an autosomal dominant disorder due to the halfnormal activity of hydroxymethylbilane synthase (HMBS), is characterized by acute neurovisceral attacks that are precipitated by factors that induce heme biosynthesis.
third enzyme in the heme biosynthetic pathway. It is the most common of the four acute hepatic porphyrias, which also include hereditary coproporphyria (HCP; OMIM#121300), variegate porphyria (VP; OMIM#176200), and the ultra-rare 5-aminolevulinic acid dehydratase deficiency porphyria (ADP), which are due to mutations in the coproporphyrinogen oxidase (CPOX), protoporphyrinogen oxidase (PPOX), and 5-aminolevulinic acid dehydratase (ALAD) genes, respectively. 1, 2 While most individuals (>90%) with the acute hepatic porphyrias are clinically latent, symptomatic individuals experience life-threatening acute neurovisceral attacks that typically begin with excruciating abdominal pain often associated with hypertension, tachycardia, constipation, motor weakness, and seizures. These attacks are precipitated by various factors, including certain drugs, fasting, and hormonal changes, all of which induce the hepatic expression of 5-aminolevulinic acid synthase 1 (ALAS1; EC 2.3.1.37), the first and rate-limiting enzyme of the heme biosynthetic pathway. [3] [4] [5] When hepatic ALAS1 is induced, the respective deficient enzymatic activity becomes rate-limiting, leading to insufficient heme production. This results in derepression and further induction of ALAS1 expression and the consequential hepatic accumulation of the putative neurotoxic porphyrin precursors, 5-aminolevulinic acid (ALA) and porphobilinogen (PBG) (only ALA accumulates in ADP), which are secreted into plasma and excreted through the urine. The biochemical diagnosis of AIP is often challenging, making mutation-based diagnoses even more important. This is particularly true of patients who previously had an acute attack but are currently asymptomatic, as their plasma and urinary ALA and PBG levels typically return to normal. For such cases, molecular diagnosis of the genes for the three autosomal dominant porphyrias, AIP, HCP, and VP is the most sensitive and specific method. 2, 6 Importantly, molecular diagnosis permits the detection of asymptomatic family members so that these individuals can be counseled to avoid factors that may precipitate acute attacks. To date, over 400 mutations causing AIP have been reported in the Human Gene Mutation Database (HGMD). 7 With the exception of founder mutations in the Netherlands and Scandinavian countries [8] [9] [10] [11] and those mutations that occur at CpG mutational hotspots, most AIP families have a 'private' mutation. Here, we report the identification of 40 novel molecular lesions in 43 unrelated individuals who had an acute attack and whose blood samples were sent to the Mount Sinai Porphyrias Diagnostic Laboratory for molecular diagnosis. All novel missense mutations and an in-frame small deletion were evaluated by prokaryotic expression to assess their pathogenicity. One missense mutation had >50% residual HMBS activity and was further assessed by thermostability assays. In addition, western blot and molecular modeling analyses were performed to investigate how each of the missense mutations affected HMBS protein stability and structure.
| MATERIALS AND METHODS
2.1 | DNA isolation and mutation analyses 
| Generation and expression of HMBS constructs in E. coli
The full-length human HMBS cDNA was cloned into the pkk vector and designated pkk-WT. 12 Mutant constructs pkk-L30P (c.89T>C), pkk-F77L (c.231T>G), pkk-A112P (c.334G>C), pkk-A122D (c.365C>A), pkk-T145I (c.434C>T), pkk-L154P (c.461 T>C), pkk-L170P (c.509 T>C), pkk-Q204HΔ3 (c.604_612del9), pkk-V224E (c.671 T>A), pkk-D240G (c.719A>G), pkk-A347P (c.1039G>C), and pkk-639del3 (c.639_641delTGC) were generated by site-directed mutagenesis (Agilent, Santa Clara, CA, USA) using primers provided in Supplementary Table 2. The constructs were confirmed by sequencing and transformed into BL21 E. coli (Promega, Madison, WI, USA), which were cultured overnight in LB medium with 0.2% (w/v) glucose. A 1:100 dilution was freshly cultured on the second day until OD 600 reached 0.5-0. 
| HMBS enzyme activity and thermostability assays
HMBS enzyme activities were determined in the supernatants as previously described [12] [13] [14] and normalized for total protein concentrations, which were determined using the Bio-Rad DC Protein Assay kit (Philadelphia, PA, USA). All assays were performed in duplicate, and the mean values were used to calculate the percent of wildtype activity. For a semi-quantitative estimate of the cross-reacting protein (CRIM)-specific activity of individual expressed mutant HMBS enzymes, the relative HMBS and GAPDH protein amounts were determined from the western blot using densitometric analyses (Fiji ImageJ software; Ref. 15 ), and the ratios of the two proteins were used to normalize the expressed HMBS activity (i.e., the CRIM-specific HMBS activities). For thermostability assays, wildtype and mutant lysates were incubated at 65 C and aliquots were taken at 0 and 90 min and placed on ice. HMBS enzyme activities for each sample were then determined.
| Western blot analysis
Protein lysates (~3 μg) were mixed with loading buffer (62.5 mM Tris-HCl, 2.5% SDS, 0.002% Bromophenol Blue, 5% β-mercaptoethanol, 10% glycerol, pH 6.8) and denatured, separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to a polyvinylidene difluoride (PVDF) membrane. The membranes were blocked with 5% non-fat dry milk in buffer (50 mM Tris, 150 mM NaCl, pH 7.6, and 0.05% Tween-20) for 1 h at room temperature and incubated with anti-HMBS antibody (Abcam, cat# ab129092, Cambridge, MA, USA) for 1 h at 4 C (1:30,000 dilution), and then incubated with secondary HRP-conjugated anti-rabbit IgG antibodies (1:100,000 dilution) for 20 min at room temperature. Signals were detected using the Chemiluminescence HRP substrate (Millipore, Burlington, MA, USA). The membranes were stripped and re-probed with anti-GAPDH (Thermo Fisher Scientific, Waltham, MA, USA) at 1:5000 dilution and secondary HRP-conjugated anti-mouse IgG antibodies (1:50,000 dilution) for loading normalization.
| Mapping of the missense mutations on the human HMBS crystal structure
The 2.2-Å crystal structure of human HMBS (PDB 3ECR) 14 was viewed in PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC). The structure has the dipyrromethane cofactor bound at the active site. 14 The molecular mutations were made using PyMOL, and the distances from the active site to the different mutations were determined using the distance feature of the software. All graphical representations were made using PyMOL.
3 | RESULTS
| Mutation detection of the HMBS gene
Genomic DNA was isolated from 43 unrelated individuals with either elevated urinary ALA or PBG levels or with clinical symptoms consistent with an acute hepatic porphyria. Each patient's HMBS gene was PCR-amplified and sequenced for all 15 exonic and adjacent intronic regions. Molecular analysis of each patient's PPOX and CPOX genes revealed normal sequences other than known common single nucleotide polymorphisms. The 40 novel HMBS mutations identified included 11 missense, four nonsense, six small duplication/insertions, ten small deletions, eight consensus splice site mutations, and a complex insertion-deletion mutation. None of the identified missense mutations occurred at a CpG dinucleotide site. As shown in Table 1 , which summarizes the 40 mutations and patient information, two of the 
Of interest, the c.612G>T (p.Q204H) missense mutation occurred at the last nucleotide of exon 10. RT-PCR analysis of mRNA isolated from the patient's blood sample indicated that this mutation resulted in an aberrantly spliced HMBS transcript, which used an alternative splice donor site that was nine nucleotides upstream of the wildtype donor site and resulted in an in-frame deletion of nine nucleotides. This transcript encodes a mutant protein designated Q204HΔ3 in which the three amino acids, V202, G203, and Q204, were deleted (Figure 1 ).
| The effects of HMBS missense and inframe deletion mutations on HMBS enzyme activity and thermostability
The 11 missense mutations, including p.Q204HΔ3, and the in-frame deletion mutation (c.639_641delTGC) were expressed in E. coli to determine HMBS activities. With the exception of c.1039G>C (p.A347P), all mutants retained ≤5% of the expressed wildtype HMBS activity, confirming their pathogenicity ( Table 2 ). The p.A347P mutant had 51% of the expressed wildtype activity (Table 2) .
Thermostability assays showed that the p.A347P mutant protein retained little, if any, HMBS activity after a 90 min incubation (65 C), while the expressed wildtype enzyme retained~60% of its initial activity, indicating that the p. A347P protein was highly thermolabile (Figure 2 ).
| The effects of HMBS missense mutations on HMBS protein stability and structure
Western blot analyses showed that the mutations encoding p.L30P, p.F77L, p.T145I, p.L170P, and p.A347P proteins were expressed at levels similar to that of expressed wildtype, whereas the mutations encoding p.A112P, p.A122D, p. L154P, p.V224E, and p.D240G were expressed at significantly reduced protein levels ( Figure 3 ). Mapping the missense mutations on the crystal structure of the human HMBS enzyme showed that residues L30, T145, and L170 were all within 5.5 Å of the dipyrromethane cofactor ( Figure 4, top panel) , which is attached to the active site cysteine residue. 16 L30 and L170 reside on an α-helix, and the substitution to proline likely disrupts the helical F I G U R E 2 The p.A347P mutant protein is thermolabile. The thermostability of the WT and p.A347P enzymes was assessed by comparing their respective enzyme activity to the initial WT activity prior to thermoinactivation. The experimental results reflect the means of four independent experiments and the error bars denote 1 standard deviation structure. In contrast, the remaining residues (F77, A112, A122, L154, V224, D240, A347) all were located on the surface of the enzyme, far from the dipyrromethane cofactor and the active site ( Figure 4, bottom panel) . Notably, the F77 residue was located at the dimer interface (data not shown). Four residues (A112, A122, V224, and D240) were located in β-sheet structures, whereas F77, L154, and A347 were on α-helices (Figure 4 , bottom panel).
| DISCUSSION
The diagnosis of AIP is usually significantly delayed due to the non-specific presenting symptoms of the disorder 17 and the fact that it is a rare disease with an estimated prevalence of one in~2000 individuals but a penetrance of only~1%. 13 Once AIP is suspected, however, establishing the diagnosis is fairly straightforward, particularly during an acute attack when abnormal porphyrin precursor (i.e., ALA and PBG) and porphyrin intermediates can be documented. 1, 17 Alternatively, AIP may be diagnosed by demonstration of decreased HMBS enzymatic activity in erythrocytes. 17 However, this method is problematic, as there is significant overlap in the range of HMBS activities between affected individuals with half-normal activity and low normal range 18 and~3% of AIP heterozygotes have mutations in exon 1, 19 which is not expressed in the erythroid form of the protein due to alternative splicing in erythroid cells. 20, 21 Thus, mutation analysis of the HMBS gene has become the most useful diagnostic test, as it is highly specific and sensitive and permits the identification of AIP patients who are in between attacks as well as asymptomatic family members. Over the past 10 years, our laboratory has received requests from physicians of >1200 unrelated individuals for AIP testing. Of those with pathogenic HMBS mutations, here, we report the identification of 40 novel HMBS mutations from 43 unrelated individuals with elevated ALA and/or PBG or symptoms compatible with an acute hepatic porphyria. Consistent with previous reports, 8,22-26 the majority of the patients in our study were female, with a female to male ratio of 38/5 (Table 1) . With the exception of the c.639_641delTGC mutation, which was in-frame but expressed no residual HMBS activity in vitro (Table 2) , and the c.1084delT mutation, all deletions, insertions, and the complex indel mutation were frame-shift mutations predicted to result in premature stop codons. Consequentially, these mutations either triggered nonsense mediated decay (NMD) and were degraded at the mRNA level, or they generated truncated non-functional HMBS polypeptide chains. The c.1084delT mutation disrupted the stop codon and was predicted to result in no-go decay 27 of the transcript or a mutant HMBS protein that was 180 amino acids longer than the normal enzyme. Notably, all eight splice site mutations RT-PCR studies on the patient's isolated total RNA confirmed the use of this upstream splice site, resulting in an alternative HMBS transcript with an in-frame deletion of the last nine nucleotides (Figure 1 ). The resultant protein lacking amino acids V202, G203, and Q204 (Q204HΔ3), had no residual enzyme activity (Table 2) . Interestingly, the expressed Q204H protein retained~80% of wildtype HMBS activity when the alternative splicing error is not present (data not shown), indicating that a glutamine to histidine substitution at this position has minimal impact on the enzymatic activity. These findings underscore the importance of performing both qualitative and quantitative RNA studies when mutations are at or near exon/intron boundaries to assess whether normal splicing occurs and at what frequency.
With the exception of the mutation encoding p.A347P, which retained 51% of wildtype activity, all of the expressed mutations had ≤5% of expressed wildtype HMBS activity ( Table 2 ). The p.L30P, p.F77L, p.T145I, and p.L170P mutant proteins were detected on western blots at levels that were comparable to expressed wildtype enzyme levels (Figure 3 ), suggesting that they were relatively structurally stable at 37 C but catalytically inactive. When the HMBS activities were normalized against relative HMBS protein content (designated as semi-quantitative CRIM-specific HMBS activity), as determined by the western blot analyses (Figure 3 ), all four mutations had <1% of CRIM-specific wildtype activity, indicating that these mutations completely abolished the enzyme's catalytic activity. In line with this finding, the L30, T145, and L170 residues were in close proximity to the dipyrromethane cofactor/active site (Figure 4 top panel) . Thus, the p.L30P, p.T145I, and p. L170P mutations presumably disrupted the active site architecture, or the formation and/or binding of the dipyrromethane cofactor to the apo-HMBS enzyme. The F77 residue was located at the dimer interface, suggesting that the p.F77L mutation interfered with dimer formation but had no impact on the monomeric enzyme's stability. In contrast, protein expression of the mutations encoding p.A112P, p. A122D, p.L154P, p.V224E, and p.D240G were markedly decreased relative to expressed wildtype activity (Figure 3 ), suggesting that these alterations disrupted structural elements that are critical for proper HMBS folding. The CRIMspecific HMBS activities were~4, 3, 2, 19, and 55% of the expressed wildtype enzyme for the p.A112P, p.A122D, p. L154P, p.V224E, and p.D240G mutant enzymes, respectively. Thus, these mutant proteins presumably decreased not only the stability of the enzyme but also the catalytic activity. Interestingly, all of these residues were located at the surface of the HMBS enzyme structure, away from the dipyrromethane cofactor/active site (Figure 4 , bottom). The A347 residue also was located on the enzyme surface, at the end of the α-helix in domain 1 before the active-site loop (Figure 4, bottom) . The p.A347P enzyme protein was unique among the surface residue mutations in that it was stable at 37 C but was highly thermolabile at 65 C (Figures 2 and   3 ), suggesting that this alteration had less of an impact on overall protein folding. Notably, the p.A347P mutant protein had a CRIM-specific activity comparable to the expressed wildtype enzyme, indicating that this mutation decreased the enzyme's stability but had no impact on its catalytic ability. To date, a total of 414 HMBS mutations have been reported in the Human Gene Mutation Database (version 2017.v3). These studies increased the total number of HMBS mutations to 454 (a 9.7% increase) ( Table 3 ). In vitro studies of the 11 missense mutations and one in-frame deletion confirmed the pathogenicity of these lesions. These studies facilitated the molecular diagnoses of AIP family members and further expanded the molecular heterogeneity of this acute hepatic porphyria.
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